

Prostate Biopsy Bibliography*

Transperineal template-based prostate biopsy

Valerio M, Anele C, Freeman A, Jameson C, Singh PB, Hu Y, Emberton M, Ahmed HU. [Identifying the index lesion with template prostate mapping biopsies.](#) *J Urol.* 2015 Apr;193(4):1185-90.

Abdi H, Zargar H, Goldenberg SL, Walshe T, Pourmalek F, Eddy C, Chang SD, Gleave ME, Harris AC, So AI, Machan L, Black PC. [Multiparametric magnetic resonance imaging-targeted biopsy for the detection of prostate cancer in patients with prior negative biopsy results.](#) *Urol Oncol.* 2015 Apr;33(4):165.

Kim EH, Vemana G, Johnson MH, Vetter JM, Rensing AJ, Strother MC, Fowler KJ, Andriole GL. [Magnetic resonance imaging-targeted vs. conventional transrectal ultrasound-guided prostate biopsy: Single-institution, matched cohort comparison.](#) *Urol Oncol.* 2015 Mar;33(3):109.

Tran M, Thompson J, Böhm M, Pulbrook M, Moses D, Shnier R, Brenner P, Delprado W, Haynes AM, Savdie R, Stricker PD. [Combination of multi-parametric magnetic resonance imaging \(mp-MRI\) and transperineal template-guided mapping biopsy \(TTMB\) of the prostate to identify candidates for hemi-ablative focal therapy.](#) *BJU Int.* 2015 Feb 14.

Sivaraman A, Sanchez-Salas R, Barret E, Ahallal Y, Rozet F, Galiano M, Prapotnich D, Cathelineau X. [Transperineal template-guided mapping biopsy of the prostate.](#) *Int J Urol.* 2015 Feb;22(2):146-51.

Sandler K, Patel M, Lynne C, Parekh DJ, Punnen S, Jorda M, Casillas J, Pollack A, Stoyanova R. [Multiparametric-MRI and Targeted Biopsies in the Management of Prostate Cancer Patients on Active Surveillance.](#) *Front Oncol.* 2015 Jan 26;5:4.

Radtke JP, Kuru TH, Boxler S, Alt CD, Popeneciu IV, Huettenbrink C, Klein T, Steinemann S, Bergstraesser C, Roethke M, Roth W, Schlemmer HP, Hohenfellner M, Hadaschik BA. [Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance.](#) *J Urol.* 2015 Jan;193(1):87-94.

Ménard C, Iupati D, Publicover J, Lee J, Abed J, O'Leary G, Simeonov A, Foltz WD, Milosevic M, Catton C, Morton G, Bristow R, Bayley A, Atenafu EG, Evans AJ, Jaffray DA, Chung P, Brock KK, Haider MA. [MR-guided prostate biopsy for planning of focal salvage after radiation therapy.](#) *Radiology.* 2015 Jan;274(1):181-91.

Mai Z, Yan W, Zhou Y, Zhou Z, Chen J, Xiao Y, Liang Z, Ji Z, Li H. [Transperineal template-guided prostate biopsy: 10 years of experience.](#) *BJU Int.* 2014 Dec 18.

Mukherjee A, Morton S, Fraser S, Salmond J, Baxter G, Leung HY. [Magnetic resonance imaging-directed transperineal limited-mapping prostatic biopsies to diagnose prostate cancer: a Scottish experience.](#) *Scott Med J.* 2014 Nov;59(4):204-8.

Sonn GA, Filson CP, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Dorey FJ, Reiter RE, Marks LS. [Initial experience with electronic tracking of specific tumor sites in men undergoing active surveillance of prostate cancer.](#) *Urol Oncol.* 2014 Oct;32(7):952-7

Nafie S, Pal RP, Dormer JP, Khan MA. [Transperineal template prostate biopsies in men with raised PSA despite two previous sets of negative TRUS-guided prostate biopsies.](#) *World J Urol.* 2014 Aug;32(4):971-5.

Merrick GS, Delatore A, Butler WM, Bennett A, Fiano R, Anderson R, Adamovich E. [Transperineal Template-guided Mapping Biopsy Identifies Pathologic Differences Between Very-Low-risk and Low-risk Prostate Cancer: Implications for Active Surveillance.](#) *Am J Clin Oncol.* 2014 Jul 25.

* This bibliography is a comprehensive selection of articles but is not necessarily an exhaustive list of literature pertaining to transperineal template-based prostate biopsy.

Lawrence EM, Tang SY, Barrett T, Koo B, Goldman DA, Warren AY, Axell RG, Doble A, Gallagher FA, Gnanapragasam VJ, Kastner C, Sala E. Prostate cancer: performance characteristics of combined T₂W and DW-MRI scoring in the setting of template transperineal re-biopsy using MR-TRUS fusion. *Eur Radiol.* 2014 Jul;24(7):1497-505.

Singh PB, Anele C, Dalton E, Barbouti O, Stevens D, Gurung P, Arya M, Jameson C, Freeman A, Emberton M, Ahmed HU. Prostate cancer tumour features on template prostate-mapping biopsies: implications for focal therapy. *Eur Urol.* 2014 Jul;66(1):12-9.

Thompson JE, Moses D, Shnier R, Brenner P, Delprado W, Ponsky L, Pulbrook M, Böhm M, Haynes AM, Hayen A, Stricker PD. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study. *J Urol.* 2014 Jul;192(1):67-74.

Vyas L, Acher P, Kinsella J, Challacombe B, Chang RT, Sturch P, Cahill D, Chandra A, Popert R. Indications, results and safety profile of transperineal sector biopsies (TPSB) of the prostate: a single centre experience of 634 cases. *BJU Int.* 2014 Jul;114(1):32-7.

Gomez JM, Garcia Rodriguez J. Optimization of prostate biopsy in patients considered for active surveillance. The role of the confirmatory biopsy and transperineal techniques. *Arch Esp Urol.* 2014 Jun;67(5):409-18.

Nafie S, Mellon JK, Dormer JP, Khan MA. The role of transperineal template prostate biopsies in prostate cancer diagnosis in biopsy naïve men with PSA less than 20 ng ml(-1). *Prostate Cancer Prostatic Dis.* 2014 Jun;17(2):170-3.

Smith JB, Popert R, Nuttall MC, Vyas L, Kinsella J, Cahill D. Transperineal sector prostate biopsies: a local anesthetic outpatient technique. *Urology.* 2014 Jun;83(6):1344-9.

Gershman B, Zietman AL, Feldman AS, McDougal WS. Transperineal template-guided prostate biopsy for patients with persistently elevated PSA and multiple prior negative biopsies. *Urol Oncol.* 2013 Oct;31(7):1093-7.

Kuru TH, Wadhwa K, Chang RT, Echeverria LM, Roethke M, Polson A, Rottenberg G, Koo B, Lawrence EM, Seidenader J, Gnanapragasam V, Axell R, Roth W, Warren A, Doble A, Muir G, Popert R, Schlemmer HP, Hadaschik BA, Kastner C. Definitions of terms, processes and a minimum dataset for transperineal prostate biopsies: a standardization approach of the Ginsburg Study Group for Enhanced Prostate Diagnostics. *BJU Int.* 2013 Sep;112(5):568-77.

Symons JL, Huo A, Yuen CL, Haynes AM, Matthews J, Sutherland RL, Brenner P, Stricker PD. Outcomes of transperineal template-guided prostate biopsy in 409 patients. *BJU Int.* 2013 Sep;112(5):585-93.

Bittner N, Merrick GS, Butler WM, Bennett A, Galbreath RW. Incidence and pathological features of prostate cancer detected on transperineal template guided mapping biopsy after negative transrectal ultrasound guided biopsy. *J Urol.* 2013 Aug;190(2):509-14.

Tsvian M, Abern MR, Qi P, Polascik TJ. Short-term functional outcomes and complications associated with transperineal template prostate mapping biopsy. *Urology.* 2013 Jul;82(1):166-70.

Bittner N, Merrick GS, Bennett A, Butler WM, Andreini HJ, Taubenslag W, Adamovich E. Diagnostic Performance of Initial Transperineal Template-guided Mapping Biopsy of the Prostate Gland. *Am J Clin Oncol.* 2013 Jun 11.

Losa A, Gadda GM, Lazzeri M, Lughezzani G, Cardone G, Freschi M, Lista G, Larcher A, Nava LD, Guazzoni G. Complications and quality of life after template-assisted transperineal prostate biopsy in patients eligible for focal therapy. *Urology.* 2013 Jun;81(6):1291-6.

Taira AV, Merrick GS, Bennett A, Andreini H, Taubenslag W, Galbreath RW, Butler WM, Bittner N, Adamovich E. Transperineal template-guided mapping biopsy as a staging procedure to select patients best suited for active surveillance. *Am J Clin Oncol.* 2013. Apr;36(2):116-20.

Kasivisvanathan V, Dufour R, Moore CM, Ahmed HU, Abd-Alazeez M, Charman SC, Freeman A, Allen C, Kirkham A, van der Meulen J, Emberton M. Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. *J Urol.* 2013 Mar;189(3):860-6.

Lecornet E, Ahmed HU, Hu Y, Moore CM, Nevoux P, Barratt D, Hawkes D, Villers A, Emberton M. The accuracy of different biopsy strategies for the detection of clinically important prostate cancer: a computer simulation. *J Urol.* 2012 Sep;188(3):974-80.

Barzell WE, Melamed MR, Cathcart P, Moore CM, Ahmed HU, Emberton M. Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer. *J Urol.* 2012 Sep;188(3):762-7.

Ayres BE, Montgomery BS, Barber NJ, Pereira N, Langley SE, Denham P, Bott SR. The role of transperineal template prostate biopsies in restaging men with prostate cancer managed by active surveillance. *BJU Int.* 2012 Apr;109(8):1170-6.

Pal RP, Elmussareh M, Chanawani M, Khan MA. The role of a standardized 36 core template-assisted transperineal prostate biopsy technique in patients with previously negative transrectal ultrasonography-guided prostate biopsies. *BJU Int.* 2012 Feb;109(3):367-71.

Ahmed HU, Hu Y, Carter T, Arumainayagam N, Lecornet E, Freeman A, Hawkes D, Barratt DC, Emberton M. Characterizing clinically significant prostate cancer using template prostate mapping biopsy. *J Urol.* 2011 Aug;186(2):458-64.

Taira AV, Merrick GS, Galbreath RW, Andreini H, Taubenslag W, Curtis R, Butler WM, Adamovich E, Wallner KE. Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. *Prostate Cancer Prostatic Dis.* 2010 Mar;13(1):71-7.



A partner for **life**

© 2015 Varian Medical Systems, Inc. All rights reserved. Varian, and Varian Medical Systems are registered trademarks of Varian Medical Systems, Inc.

Intended Use Summary

Varian Medical Systems' software, afterloaders, and applicators are intended to provide radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated.

Safety

Radiation treatments may cause side effects varying with the part of the body being treated. This may include, but not be limited to irritation to the mouth, respiratory system, digestive system, genitourinary system, fatigue, nausea, skin irritation, and hair loss. In a minority of patients, side effects can be severe. Typically, the side effects are temporary. Radiation treatment is not appropriate for all cancers. Treatment sessions may vary in complexity and time. Side effects of applicator placement and/or implantation may occur. These side effects may include, but are not limited to, localized discomfort, bleeding, and infection or other localized side effects based on the location the applicator is placed. Patients should discuss the treatment and side effects with their physicians before starting.

Medical Advice Disclaimer

Varian as a medical device manufacturer cannot and does not recommend specific treatment approaches. Individual treatment results may vary.

RAD 4258

USA Headquarters, California

Varian Medical Systems
Palo Alto, CA
Tel: 650.424.5700
800.544.4636
Fax: 650.493.5637
varian.com

Headquarters Europe, Eastern Europe, Africa, Middle & Near East

Varian Medical Systems
International AG
Cham, Switzerland
Tel: 41.41.749.8844
Fax: 41.41.749.8899
email: info.europe@varian.com

06/2015 (500)